About Diagnostic Hybrids
Diagnostic Hybrids is a company based in Athens (United States) founded in 1983 was acquired by Quidel in January 2010. Diagnostic Hybrids has raised $10 million across 1 funding round from investors including Summit Partners, Kenson Ventures and QuidelOrtho. Diagnostic Hybrids offers products and services including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems. Diagnostic Hybrids operates in a competitive market with competitors including ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others.
- Total Equity Funding$10M (USD)
in 1 rounds
- Latest Funding Round$10M (USD), Private Equity Round
Aug 2004
- InvestorsSummit Partners
& 2 more
- Acquired byQuidel
(Jan 2010)
Products & Services of Diagnostic Hybrids
Diagnostic Hybrids offers a comprehensive portfolio of products and services, including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems.
Fast test for detecting COVID-19 at home or point-of-care.
Benchtop system for rapid immunoassay and testing solutions.
Platform for efficient molecular testing in labs.
Systems for clinical chemistry and immunoassay processing.
Apps and channels of Diagnostic Hybrids
its YouTube channel QuidelOrtho has 235 subscribers and 30 videos.
Videos from Diagnostic Hybrids
The most watched videos on Diagnostic Hybrids's YouTube channel, QuidelOrtho (235 subscribers). Click a video to play it here.
More on QuidelOrtho.
Funding Insights of Diagnostic Hybrids
Diagnostic Hybrids has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $10 million completed in August 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Private Equity Round — $10M
- First Round $10M
(Aug 2004)
- Investors Count 2
All 1 funding rounds of Diagnostic Hybrids with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2004 | $10M | Private Equity Round | – | Summit Partners |
3 investors in total: 3 institutional.
Investors in Diagnostic Hybrids
Diagnostic Hybrids has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Summit Partners, Kenson Ventures and QuidelOrtho.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Summit Partners is recognized as a growth equity investment firm. | – | summitpartners.com | Boston, United States | |
- | – | kensonventures.com | - | |
QuidelOrtho is engaged in providing diagnostic testing solutions globally. | – | quidel.com | San Diego, United States |
Investor details for Diagnostic Hybrids
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Diagnostic Hybrids
3 dated milestones of Diagnostic Hybrids across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Diagnostic Hybrids is founded.
- Funding First funding round of $10.0M.
- Exit Acquired by Quidel.
Competitors of Diagnostic Hybrids
Diagnostic Hybrids operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| diagenode.com | 2003 | Seraing, Belgium | $8.45M | 99 | Reagents and kits for epigenetics sequencing solutions are developed. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| oxgene.com | 2011 | Oxford, United Kingdom | $28.09M | 102 | Provider of a platform for mammalian cell engineering |
Detailed competitors of Diagnostic Hybrids
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagnostic Hybrids
Complete news archive for Diagnostic Hybrids
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Diagnostic Hybrids
10 companies that operate in the same segment as Diagnostic Hybrids (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diagnostic Hybrids
Diagnostic Hybrids was founded in 1983 and raised its 1st funding round 21 years after it was founded.
Diagnostic Hybrids is headquartered in Athens, United States.
Diagnostic Hybrids is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $10M, raised on Aug 2004.
Diagnostic Hybrids develops and manufactures cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of diseases. The company offers a D3 FastPoint L-DFA influenza Ainfluenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patients specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.
Diagnostic Hybrids's top competitors include Sino Biological, OncoDNA and ArcherDX.
Diagnostic Hybrids offers QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems.
Diagnostic Hybrids has 3 investors. Key investors include Summit Partners, Kenson Ventures, and QuidelOrtho.
Diagnostic Hybrids operates through Quidel Corporation.
Yes. Diagnostic Hybrids was acquired by Quidel in January 2010.